HUMULIN 70/30 OTC
Generic Name and Formulations:
Insulin isophane suspension (NPH) 70% (human, rDNA origin), regular insulin 30% (human, rDNA origin) 100 Units/mL; inj.
Lilly, Eli and Company
Indications for HUMULIN 70/30:
Adults and Children:
SC injection only. Onset approx 30 mins, peak 2–12hrs, duration up to 24hrs.
Instruct patients on diet, exercise, blood or urine testing, proper administration of insulin, change in species of origin, type or purity of insulin, and management of hypoglycemia. Do not reuse or share pens, needles, or syringes between patients. Dosage increase may be required during infection, illness, stress, trauma, and pregnancy. Dosage decrease may be needed with renal or hepatic dysfunction.
Concomitant thiazolidinediones (TZDs) may cause fluid retention and heart failure; consider dose reduction or discontinue TZDs. Potentiated by oral antidiabetic agents, pramlintide, ACE inhibitors, disopyramide, fibrates, fluoxetine, MAOIs, propoxyphene, salicylates, somatostatin analog, sulfonamide antibiotics. Antagonized by corticosteroids, isoniazid, niacin, danazol, diuretics, thiazides, phenothiazines, sympathomimetics, somatropin, thyroid hormones, estrogens, progestogens, atypical antipsychotics. Variable effects with β-blockers, clonidine, lithium salts, alcohol, pentamidine. Onset may be delayed if regular insulin is mixed with zinc insulin. Regular and NPH insulins may be mixed and used immediately or stored for future use.
Hypoglycemia, hypokalemia, local or systemic allergy, lipodystrophy, edema.
Vials 70/30, N, R (U-100)—10mL; R (U-500)—20mL; KwikPen (70/30, N)—5x3mL; R (U-500)—2x3mL, 5x3mL